1. Scrip

Promising Tanibirumab Trial Boosts PharmAbcine’s Confidence

 
• By Jung Won Shin

PharmAbcine is counting on the success of its lead anticancer antibody tanibirumab following promising early Phase II results, and the South Korean bioventure is planning to raise new funds as it looks to progress this and other pipeline projects.

chart

PharmAbcine Inc. says it is receiving "remarkable" data from a Phase IIa Australian trial with tanibirumab, the South Korean bioventure’s anti-VEGFR2/KDR antibody, in an aggressive form of brain cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia